Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 7,718 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 2 Clear all
Completed Phase 1 Interventional

A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma

NCT00545519
View directory record Official record
Conditions
Relapsed Or Refractory Multiple Myeloma
Interventions
thymoglobulin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Oct 20, 2026, 10:47 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Testing Pharmacological Therapies for Pregnant Smokers

NCT00224419
View directory record Official record
Conditions
Smoking, Pregnancy
Interventions
Motivational interviewing for smoking cessation, Cognitive behaviors therapy, CBT + NRT
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
2
States / cities
Durham, North Carolina • Fayetteville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 20, 2026, 10:47 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment

NCT03682601
View directory record Official record
Conditions
Sexual Pain Disorders, Postmenopausal Symptoms, Vulvovaginal Atrophy, Female Sexual Dysfunction, Dyspareunia, Vulvodynia, Vestibulodynia, Arousal Disorders, Sexual, Genito-Pelvic Pain/Penetration Disorder, Female Sexual Arousal Disorder
Interventions
5% sinecatechins ointment, Placebo, 10% sinecatechins ointment
Drug
Lead sponsor
GTO Pharmaceutical, LLC
Other
Eligibility
20 Years to 70 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
New York, New York • Nyack, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 20, 2026, 10:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cognitive Multi-Tasking Training in Healthy Older Adults

NCT04195230
View directory record Official record
Conditions
Age-related Cognitive Decline
Interventions
Multi-tasking Training
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
60 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 20, 2026, 10:47 PM EDT
Completed Phase 1 Interventional

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

NCT04257110
View directory record Official record
Conditions
Locally Advanced/Metastatic HER2 Positive Solid Tumors
Interventions
BB-1701
Drug
Lead sponsor
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
San Francisco, California • Nashville, Tennessee • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 20, 2026, 10:47 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab, Daratumumab, Lenalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
17
States / cities
Jupiter, Florida • Lincoln, Nebraska • Reno, Nevada + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 10:47 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ruxolitinib for Adult T-Cell Leukemia

NCT01712659
View directory record Official record
Conditions
T Cell Leukemia, Adult, Leukemia, Adult T-Cell, T Cell Leukemia, HTLV I Associated
Interventions
Ruxolitinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 20, 2026, 10:47 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Reading Outcomes in Children With Vestibular Loss

NCT05414903
View directory record Official record
Conditions
Vestibular Disorder, Hearing Loss, Sensorineural
Interventions
Dynamic Visual Acuity, Reading Outcomes, Static Visual Acuity
Behavioral
Lead sponsor
Father Flanagan's Boys' Home
Other
Eligibility
7 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 20, 2026, 10:47 PM EDT
Completed No phase listed Observational

Blood Factors and Diabetic Retinopathy

NCT00005761
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
10 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 10:47 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT04539470
View directory record Official record
Conditions
Acute Graft-versus-host Disease
Interventions
Efmarodocokin Alfa
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Duarte, California • Los Angeles, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 20, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Results available

A Study Of PF-03732010 In Patients With Advanced Solid Tumors

NCT00557505
View directory record Official record
Conditions
Neoplasms
Interventions
PF-03732010
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Oct 20, 2026, 10:47 PM EDT
Completed Phase 1 Interventional

SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

NCT01385956
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
SOM 230 LAR, Gemcitabine
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Oct 20, 2026, 10:47 PM EDT
Completed No phase listed Observational

mRNA Based-Covid-19 Vaccine Effects on Blood Glucose Levels

NCT04923386
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Hyperglycemia, Vaccine Adverse Reaction
Interventions
None (not interventional)
Other
Lead sponsor
Levenson, David I., M.D.
Individual
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Oct 20, 2026, 10:47 PM EDT
Completed Not applicable Interventional

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

NCT01505569
View directory record Official record
Conditions
Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
Interventions
Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
Drug · Biological · Radiation + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 20, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00639769
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, irinotecan hydrochloride
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
8
States / cities
Macon, Georgia • Chattanooga, Tennessee • Jackson, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 20, 2026, 10:47 PM EDT
Recruiting Not applicable Interventional

Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

NCT06957366
View directory record Official record
Conditions
Atrial Fibrillation (AF), VTE
Interventions
PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
Other
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Hartford, Connecticut • Evanston, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 20, 2026, 10:47 PM EDT
Recruiting Not applicable Interventional

Pilot SMART of a Remotely Delivered, Physical Activity Intervention for Breast Cancer Survivors

NCT07706556
View directory record Official record
Conditions
Breast Cancer
Interventions
Affect-based Exercise Prescription, Effort-based exercise prescription, Standard Exercise Promotion Program, Step-up Exercise Promotion Program
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 20, 2026, 10:47 PM EDT
Recruiting Phase 1Phase 2 Interventional

Low Dose IL-2 for the Treatment of Crohn's Disease

NCT04263831
View directory record Official record
Conditions
Crohn Disease
Interventions
Interleukin-2 (aldesleukin).
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 20, 2026, 10:47 PM EDT
Not listed Phase 1Phase 2 Interventional

Quantitating the Impact of Plerixafor

NCT02522572
View directory record Official record
Conditions
Transplants and Implants
Interventions
plerixafor, Bortezomib, plasmapheresis
Drug · Other
Lead sponsor
E. Steve Woodle
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 20, 2026, 10:47 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

NCT06619990
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
XmAb942, Placebo
Biological · Drug
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
30
States / cities
Scottsdale, Arizona • Palo Alto, California • Bradenton, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 10:47 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

NCT05607420
View directory record Official record
Conditions
B-cell Non-Hodgkin Lymphoma (B-NHL)
Interventions
UCART20x22, CLLS52
Biological
Lead sponsor
Cellectis S.A.
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 20, 2026, 10:47 PM EDT
Completed Not applicable Interventional Results available

The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes

NCT04796779
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tandem t:slim X2 with Control-IQ Technology Pro, Standard Care (SC), Tandem t:slim X2 with Control-IQ Technology V1.5
Device
Lead sponsor
Marc Breton
Other
Eligibility
24 Months to 71 Months
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 20, 2026, 10:47 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

NCT00203996
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions
continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp
Device · Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 20, 2026, 10:47 PM EDT
Recruiting Phase 1 Interventional

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

NCT06401603
View directory record Official record
Conditions
Advanced Chronic Myeloid Leukemia, Philadelphia Chromosome-Positive Acute Myeloid Leukemia
Interventions
Decitabine, Listaftoclax, Olverembatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 10:47 PM EDT